Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Patrick Daly
Patrick Daly is an Assistant Editor at AMC Media Group.
Articles by Patrick Daly
Dr. Usmani Highlights Myeloma Presentations from SOHO 2024
Saad Z. Usmani, MD, MBA, FACP
The HemOnc Pulse
|
November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Listen Now
Pivekimab Sunirine Shows Promise for AML in Phase I/II Trial
Patrick Daly
Acute Myeloid Leukemia
|
November 12, 2024
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Read More
Isolating CD34-Positive Samples: MRD Analysis in MDS
Patrick Daly
Meeting News
|
November 4, 2024
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Read More
Covering MDS Updates at SOHO 2024 With Dr. Venugopal
Sangeetha Venugopal, MD
The HemOnc Pulse
|
November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Listen Now
Study Analyzes Step-Up Dosing With Talquetamab in Real-World Patients
Patrick Daly
Myeloma
|
October 31, 2024
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Read More
Talquetamab Plus Pomalidomide Achieves Effective Responses in MonumenTAL-2
Patrick Daly
Myeloma
|
October 31, 2024
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
Read More
Enrollment Begins for Phase III iMMagine-3 Trial on Anito-Cel in Myeloma
Patrick Daly
Myeloma
|
October 31, 2024
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
Read More
Survey Defines Patient Preferences in BCMA-Directed T-Cell Engagers
Patrick Daly
Myeloma
|
October 31, 2024
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
Read More
Discussing the Impact of Luspatercept on Cell Lineages in MDS
Jamile Shammo, MD
Myelodysplastic Syndromes
|
October 29, 2024
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
View More
Dr. Swoboda on the Importance of MDS World Awareness Day
David Swoboda, MD
Myelodysplastic Syndromes
|
October 21, 2024
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
View More
Potential Benefits of Selinexor for CAR-T Therapies
Adriana Rossi, MD
Myeloma
|
October 16, 2024
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
View More
AML News From SOHO 2024 With Dr. Daver
Naval Daver, MD
The HemOnc Pulse
|
October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Listen Now
Dr. Abid on Sequencing Pirtobrutinib After CAR-T
Melissa Badamo
Transplantation & Cellular Therapy
|
October 4, 2024
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
View More
Dr. Luminari Remarks on EU Approval of Odronextamab for DLBCL, Follicular Lymphoma
Stefano Luminari, MD
Aggressive B-Cell Lymphoma
|
October 3, 2024
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
View More
Dr. Kittai on Sequencing Pirtobrutinib With CAR-T for CLL
Adam Kittai, MD
Chronic Lymphocytic Leukemia
|
October 8, 2024
Adam Kittai, MD, discusses sequencing pirtobrutinib and CAR-T in the management of CLL with Richter transformation.
View More
Dr. Kittai Discusses Richter Transformation in CLL: Unmet Needs, Novel Therapies
Adam Kittai, MD
Chronic Lymphocytic Leukemia
|
October 9, 2024
Adam Kittai, MD, of the Icahn School of Medicine, describes three trials on novel therapies for Richter transformation.
View More
Bilal Abid, MD, Discusses Bispecifics Versus CAR-T in the Community Setting
Melissa Badamo
Transplantation & Cellular Therapy
|
October 24, 2024
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
View More
Dr. Shadman Shares SOHO 2024 Data On CLL
Mazyar Shadman, MD, MPH
The HemOnc Pulse
|
September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Listen Now
COVID-19 Infection Correlated With MDS Disease Features
Patrick Daly
Myelodysplastic Syndromes
|
September 26, 2024
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
Read More
Inhibitor Therapy Shows Significant Survival Benefit in IDH1-Mutated MDS
Patrick Daly
Myelodysplastic Syndromes
|
September 26, 2024
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Read More
Load More